EDS hypermobility POTS MCAS autoimmune cardiovascular inflammation connective tissue

The EDS–POTS–MCAS Trifecta: Why Hypermobile Patients Need a Different Plan

By UltraSkool Research Team • May 10, 2026 • Updated May 10, 2026
The EDS–POTS–MCAS Trifecta: Why Hypermobile Patients Need a Different Plan

Twenty years ago, hypermobile patients were diagnosed with anxiety. Then with chronic fatigue. Then with fibromyalgia. The pattern repeats because clinicians keep meeting the same phenotype: a young, often female, hypermobile patient with dysautonomia, GI dysfunction, food intolerances, palpitations, and unpredictable flares. The pattern has a name now — the EDS-POTS-MCAS trifecta — and it has biology behind it.

The Three Conditions, Briefly

  • Hypermobile Ehlers-Danlos Syndrome (hEDS) / Hypermobility Spectrum Disorder (HSD) — a connective tissue disorder affecting collagen integrity. Joints, skin, blood vessels, and organ supporting tissues are all involved.
  • Postural Orthostatic Tachycardia Syndrome (POTS) — autonomic dysfunction defined by heart rate rise ≥30 bpm on standing (≥40 in adolescents) without orthostatic hypotension, with associated symptoms.
  • Mast Cell Activation Syndrome (MCAS) — inappropriate mast cell mediator release causing multisystem symptoms.

The Numbers

The overlap is not subtle. Roughly 80% of hEDS patients also have POTS. Approximately 31% of POTS patients have hEDS. And in patients with both POTS and EDS, the prevalence of MCAS rises to about 31% — compared with 2% in patients without POTS or EDS. These are not coincidences. They are mechanistic links.

Why the Three Cluster: The Biology

Connective tissue → autonomic dysfunction

Blood vessels are connective tissue. When the collagen scaffold is weak, vessel elasticity changes, venous distensibility increases, and gravity-dependent blood pooling becomes severe. The autonomic nervous system tries to compensate with sympathetic hyperdrive, producing the characteristic tachycardia, fatigue, and lightheadedness.

Connective tissue → mast cells

Mast cells are tissue-resident immune cells embedded in connective tissue. Altered collagen structure may change the mechanical and biochemical environment in which mast cells reside, predisposing to inappropriate activation. Recent 2025 proteomics work in hEDS shows reduced complement proteins, suggesting an intrinsic immune-system component to the connective tissue picture.

Autonomic dysfunction ↔ mast cells

Mast cell mediators directly affect autonomic balance — histamine raises sympathetic outflow, depresses vagal tone, and contributes to orthostatic intolerance. Conversely, low vagal tone removes the cholinergic brake on mast cells. The two conditions feed each other in a self-amplifying loop.

The Workup I Run

  • Beighton score and 2017 hEDS criteria.
  • 10-minute active stand test with BP and HR — most reliable POTS screen.
  • Tilt-table if active stand is borderline.
  • Mast cell mediator panel — tryptase, plasma histamine, urinary N-methylhistamine, prostaglandin D2 metabolites.
  • HRV trend over 1–2 weeks.
  • Iron, ferritin, B12, vitamin D — frequently low in this population.
  • Echocardiogram — to rule out vascular EDS and assess mitral valve.

The Sequenced Treatment Plan

1. Address POTS first (most reversible)

  • Aggressive volume restoration: 2.5–3 L water, 8–10 g sodium daily.
  • Medical compression garments (20–30 mmHg, waist-high).
  • Recumbent exercise to build conditioning without orthostatic stress.
  • Selective pharmacology when needed: ivabradine, midodrine, low-dose beta-blockade.

2. Stabilize the mast cell

  • H1 + H2 antihistamines.
  • Cromolyn sodium, quercetin, luteolin.
  • Identify and remove triggers — but avoid the restriction trap.

3. Restore vagal tone (treats both)

  • Slow breathing protocols, HRV biofeedback.
  • Transcutaneous auricular vagus nerve stimulation — directly relevant in this population because it modulates both autonomic and mast cell axes through the cholinergic anti-inflammatory pathway.

4. Support connective tissue and mitochondria

  • Targeted nutrition: vitamin C (collagen cofactor), magnesium, B-complex, CoQ10.
  • Strength training in protected ranges — improves joint stability and muscle pump.
  • Sleep optimization and pacing during flares.

What This Population Should Avoid

  • Aggressive end-range stretching ("yoga as treatment") — destabilizes joints further.
  • Generic "exercise to fix fatigue" recommendations — produces post-exertional flares.
  • Restrictive diets without a clinical rationale — common path into nutritional deficiency.
  • Dismissive "it's anxiety" framing — both clinically wrong and corrosive to the therapeutic relationship.

Clinical takeaway: The trifecta cluster is mechanistic, not coincidental. Treat the autonomic state first because it is the most modifiable. Stabilize the mast cell. Rebuild vagal tone. The connective tissue is the substrate — you cannot change it, but you can change the system that sits on top of it.

References

  1. Kohn A, Chang C. "The relationship between hypermobile Ehlers-Danlos syndrome, postural orthostatic tachycardia syndrome, and mast cell activation syndrome." Clinical Reviews in Allergy & Immunology, 2020;58(3):273-297.
  2. Wang E et al. "The relationship between mast cell activation syndrome, postural tachycardia syndrome, and Ehlers-Danlos syndrome." Allergy and Asthma Proceedings, 2021;42(3):243-246.
  3. Tinkle BT et al. "Hypermobile Ehlers-Danlos syndrome (a.k.a. Ehlers-Danlos syndrome type III) and the hypermobility spectrum disorders." American Journal of Medical Genetics, 2017;175C(1):48-69.
  4. Miller AJ et al. "Reduced cerebral blood flow in postural orthostatic tachycardia syndrome." Hypertension, 2020;75:1213-1219.
  5. Caringi M et al. "Mast cells in the autonomic nervous system." Annals of Allergy, Asthma & Immunology, 2024;132(4):440-449.

Connect with us:

Twitter YouTube
Back to all posts

Related Posts